Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 201

1.

Relationship between adherence level, type of the antiretroviral regimen, and plasma HIV type 1 RNA viral load: a prospective cohort study.

Martin M, Del Cacho E, Codina C, Tuset M, De Lazzari E, Mallolas J, Miró JM, Gatell JM, Ribas J.

AIDS Res Hum Retroviruses. 2008 Oct;24(10):1263-8. doi: 10.1089/aid.2008.0141.

PMID:
18834323
2.

Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes.

Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G.

Ann Intern Med. 2007 Apr 17;146(8):564-73.

PMID:
17438315
3.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
4.
5.

Effect of adherence to HAART on virologic outcome and on the selection of resistance-conferring mutations in NNRTI- or PI-treated patients.

Maggiolo F, Airoldi M, Kleinloog HD, Callegaro A, Ravasio V, Arici C, Bombana E, Suter F.

HIV Clin Trials. 2007 Sep-Oct;8(5):282-92.

PMID:
17956829
6.

Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies.

Braithwaite RS, Kozal MJ, Chang CC, Roberts MS, Fultz SL, Goetz MB, Gibert C, Rodriguez-Barradas M, Mole L, Justice AC.

AIDS. 2007 Jul 31;21(12):1579-89.

7.
8.

Concurrent use of comedications reduces adherence to antiretroviral therapy among HIV-infected patients.

Cantudo-Cuenca MR, Jiménez-Galán R, Almeida-Gonzalez CV, Morillo-Verdugo R.

J Manag Care Spec Pharm. 2014 Aug;20(8):844-50.

9.
10.

Influence of prior antiretroviral experience on adherence and responses to new highly active antiretroviral therapy regimens.

Horberg M, Silverberg M, Hurley L, Delorenze G, Quesenberry C.

AIDS Patient Care STDS. 2008 Apr;22(4):301-12. doi: 10.1089/apc.2007.0101.

PMID:
18338961
11.

Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort study.

Di Giambenedetto S, Torti C, Prosperi M, Manca N, Lapadula G, Paraninfo G, Ladisa N, Zazzi M, Trezzi M, Cicconi P, Corsi P, Nasta P, Cauda R, De Luca A; UCSC cohort; MASTER cohort; ARCA cohort.

Infection. 2009 Oct;37(5):438-44. doi: 10.1007/s15010-009-8237-x. Epub 2009 Aug 7.

PMID:
19669091
12.

Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy.

Humphreys EH, Chang LW, Harris J.

Cochrane Database Syst Rev. 2010 Jun 16;(6):CD006517. doi: 10.1002/14651858.CD006517.pub3. Review.

PMID:
20556768
13.

Comparison of HIV Virologic Failure Rates Between Patients with Variable Adherence to Three Antiretroviral Regimen Types.

Gordon LL, Gharibian D, Chong K, Chun H.

AIDS Patient Care STDS. 2015 Jul;29(7):384-8. doi: 10.1089/apc.2014.0165. Epub 2015 Jun 4.

PMID:
26114665
14.

Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types.

von Wyl V, Yerly S, Böni J, Bürgisser P, Klimkait T, Battegay M, Furrer H, Telenti A, Hirschel B, Vernazza PL, Bernasconi E, Rickenbach M, Perrin L, Ledergerber B, Günthard HF; Swiss HIV Cohort Study.

Arch Intern Med. 2007 Sep 10;167(16):1782-90.

PMID:
17846398
15.

Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.

Aziz N, Sokoloff A, Kornak J, Leva NV, Mendiola ML, Levison J, Feakins C, Shannon M, Cohan D.

BJOG. 2013 Nov;120(12):1534-47. doi: 10.1111/1471-0528.12226. Epub 2013 Aug 7.

16.

Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study.

Ruiz L, Negredo E, Domingo P, Paredes R, Francia E, Balagué M, Gel S, Bonjoch A, Fumaz CR, Johnston S, Romeu J, Lange J, Clotet B; Spanish Lipodystrophy Group.

J Acquir Immune Defic Syndr. 2001 Jul 1;27(3):229-36.

PMID:
11464141
17.

Impact of an adherence program to antiretroviral treatment on virologic response in a cohort of multitreated and poorly adherent HIV-infected patients in Spain.

Navarro J, Pérez M, Curran A, Burgos J, Feijoo M, Torrella A, Caballero E, Ocaña I, Ribera E, Crespo M, Falcó V.

AIDS Patient Care STDS. 2014 Oct;28(10):537-42. doi: 10.1089/apc.2014.0097. Epub 2014 Aug 11.

PMID:
25111167
18.

Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study.

Matthews GV, Sabin CA, Mandalia S, Lampe F, Phillips AN, Nelson MR, Bower M, Johnson MA, Gazzard BG.

AIDS. 2002 Jan 4;16(1):53-61.

PMID:
11741163
19.

Predictors of virologic failure in HIV-1-infected patients starting highly active antiretroviral therapy in Porto Alegre, Brazil.

Tuboi SH, Harrison LH, Sprinz E, Albernaz RK, Schechter M.

J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):324-8.

PMID:
16249707
20.

The risk of virologic failure decreases with duration of HIV suppression, at greater than 50% adherence to antiretroviral therapy.

Rosenblum M, Deeks SG, van der Laan M, Bangsberg DR.

PLoS One. 2009 Sep 29;4(9):e7196. doi: 10.1371/journal.pone.0007196.

Supplemental Content

Support Center